## AMENDMENTS TO THE ABSTRACT

Please replace the Abstract as filed with the following:

## Abstract

A medicament having an action of inhibiting activation of transcription factor KLF5 and thus inhibiting vascular remodeling and arteriosclerosis, which comprises an acyclic polyprenyl compound (e.g., polyprenylcarboxylic acid such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid and the like) as an active ingredient.